Zevra Therapeutics, Inc.
As of Oct 22, 2026, Zevra Therapeutics is in Stage 3, the topping phase, now in week 9 (since Aug 20, 2026). It closed at $10.33, 30.0% below its 52-week high and below its 200-day average, which is rising.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ZVRA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ZVRA among Biotechnology212th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …212 | ZVRA | Stage 3 · wk 9 | 48 | −8.7% |
Zevra Therapeutics: quick answers
What stage is Zevra Therapeutics in?
As of Oct 22, 2026, Zevra Therapeutics (ZVRA) is in Stage 3, the topping phase. It entered Stage 3 on Aug 20, 2026 and is in week 9. What the four stages mean
Is Zevra Therapeutics in an uptrend?
Its uptrend has stalled. Zevra Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 3.5% below its 200-day average, which is rising.
How far is Zevra Therapeutics from its 52-week high?
Zevra Therapeutics closed at $10.33 on Oct 22, 2026, 30.0% below its 52-week high of $14.75. Its 52-week low is $8.10.
How has Zevra Therapeutics performed over the past year?
As of Oct 22, 2026, Zevra Therapeutics is down 6.9% over the past year and up 23.9% so far in 2026.
Which sector and industry is Zevra Therapeutics in?
Zevra Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.